About
As the Penn Medicine Co-Investment Program’s inaugural Director, Carter drives Penn Medicine's investments in the cell therapy, gene therapy, mRNA, lipid nanoparticle, and connected health spinouts. Utilizing multiple decades of experience as both an entrepreneur and an investor, he sources investment opportunities, helps spinouts raise capital, manages relationships with co-investors, completes due diligence, and supports the governance of the funded companies. Carter has spent much of his career in venture capital and focused on new investments in the Healthcare IT, SaaS and Enterprise Software, AI, and Fintech industries, among others. He was previously a Managing Director with Cross Atlantic Capital Partners, a venture capital firm with 4 funds and over $500 million under management. He has a strong technology background, having founded and managed two software companies. Carter founded and served as COO of Quazant Technology, the developer of the Transaction Accelerator®, a high
Position in the VCSift Database
- • 4 investors hold the Program Director role in VCSift. Carter Caldwell is one of them.
- • 510 investors are based in Philadelphia, Pennsylvania, United States.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- Philadelphia, US
Contact Information
Find more investors like Carter
Search Investors